Aptose Biosciences (NASDAQ:APTO) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report issued on Monday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $2.00 target price on shares of Aptose Biosciences in a report on Tuesday, December 10th.

Aptose Biosciences Stock Up 63.9 %

Shares of APTO stock opened at $0.28 on Monday. Aptose Biosciences has a 12 month low of $0.13 and a 12 month high of $2.68. The company’s fifty day simple moving average is $0.30 and its 200-day simple moving average is $0.47. The firm has a market cap of $16.79 million, a PE ratio of -0.09 and a beta of 1.06.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp boosted its position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.